Key facts
- It has raised $110.3M across 2 recorded rounds; the latest was Early Stage VC ($15.3M) in Dec 2023.
- Notable investors include Lightspeed Venture Partners, The Invus Group, Samsara BioCapital, Bristol-Myers Squibb, Third Rock Ventures — 8 tracked in total.
- Abata Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Dec 2023 ($15.3M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Abata Therapeutics
Funding rounds
2 roundsAbout Abata Therapeutics
Developer of cell therapy intended to treat autoimmune and inflammatory diseases. The company offers therapies to express t-cell receptors that recognize antigens present in tissue to target the site of disease for a robust effect without imposing systemic immune suppression, enabling patients to maintain a stable and stimulated tissue residency.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2021
- Employees
- 46
- Website
- abatatx.com/
- Ownership
- Privately Held (backing)
Abata Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abata Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abata Therapeutics in its N-PORT filings yet. We sweep new filings monthly.